A HPLC-DAD method to facilitate large-scale therapeutic drug monitoring of dalbavancin.


Journal

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
ISSN: 1873-376X
Titre abrégé: J Chromatogr B Analyt Technol Biomed Life Sci
Pays: Netherlands
ID NLM: 101139554

Informations de publication

Date de publication:
01 May 2023
Historique:
received: 10 11 2022
revised: 08 03 2023
accepted: 26 03 2023
medline: 16 5 2023
pubmed: 16 4 2023
entrez: 15 4 2023
Statut: ppublish

Résumé

Dalbavancin, a long-acting lipoglycopeptide antibiotic targeting susceptible Gram-positive bacteria, is WHO critically important antibiotic, increasingly used in critical situations such as osteoarticular infections. To ensure its effectiveness and its safety, the therapeutic drug monitoring (TDM) of dalbavancin is strongly recommended. In the absence of an available minimum inhibitory concentration (MIC), the European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommends a breakpoint of 0.125 mg/L for Staphylococcus aureus, corresponding to a trough target concentration of 25 mg/L. Nowadays, the TDM is usually performed using a high-performance liquid chromatography (HPLC) method coupled with a tandem mass spectrometry. However, this expensive and specialized equipment and reagents may be difficult to acquire for non-specialized laboratories. The use of HPLC coupled with diode array detector (DAD) facilitates TDM with a lower cost, while preserving the reliability of the results. Our aim was to provide a sensitive and specific method, relying on HPLC-DAD for extending the TDM of dalbavancin beyond non-specialized labs, therefore maximizing its efficiency and Benefit/risk ratio. Our method complied with the European Medicines Agency guidelines of bioanalytical validation. Irrespective of the concentrations of dalbavancin, the coefficient of variation < 10% confirmed the reliability of this analytical method, with a calibration curve ranging from 5 to 100 mg/L. No interferences nor carryover was observed. Our HPLC-DAD method, combined with a simple extraction, provides a widely usable, inexpensive and easy-to-implement new asset for the TDM of Dalbavancin.

Identifiants

pubmed: 37060815
pii: S1570-0232(23)00104-6
doi: 10.1016/j.jchromb.2023.123694
pii:
doi:

Substances chimiques

dalbavancin 808UI9MS5K
Teicoplanin 61036-62-2
Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123694

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Alexandre Destere (A)

Department of Pharmacology and Pharmacovigilance Center, Côte d'Azur University Medical Center, Nice, France.

Diane Merino (D)

Department of Pharmacology and Pharmacovigilance Center, Côte d'Azur University Medical Center, Nice, France.

Laurent Bonesso (L)

Department of Pharmacology and Pharmacovigilance Center, Côte d'Azur University Medical Center, Nice, France.

Thibaud Lavrut (T)

Department of Pharmacology and Pharmacovigilance Center, Côte d'Azur University Medical Center, Nice, France.

Anaïs Bernasconni (A)

Department of Pharmacology and Pharmacovigilance Center, Côte d'Azur University Medical Center, Nice, France.

Rodolphe Garraffo (R)

Department of Pharmacology and Pharmacovigilance Center, Côte d'Azur University Medical Center, Nice, France.

Alexandre O Gérard (AO)

Department of Pharmacology and Pharmacovigilance Center, Côte d'Azur University Medical Center, Nice, France.

Milou-Daniel Drici (MD)

Department of Pharmacology and Pharmacovigilance Center, Côte d'Azur University Medical Center, Nice, France. Electronic address: pharmacovigilance@chu-nice.fr.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Humans Middle Aged Female Male Surveys and Questionnaires

Classifications MeSH